| HRA005122
(Controlled Access)
|
We conducted a multicenter, phase 2 study to investigate the efficacy of neoadjuvant chemo-immunotherapy (NACIT) for LACC. Eligible patients underwent one cycle of priming chemotherapy followed by two cycles of combination chemotherapy with camrelizumab. The primary endpoint included the objective response rate, while key secondary endpoints were pathological complete response (pCR), patients requiring postoperative adjuvant therapy (PAT), and safety profiles. Exploratory endpoints were pre-treatment biomarker for response and dynamic panoramas of intratumoral infiltrating immune cells. This study is registered with ClinicalTrials.gov, NCT04516616. |
